CN103703372B - 抗‑人受体类型蛋白酪氨酸磷酸酶σ抗体 - Google Patents
抗‑人受体类型蛋白酪氨酸磷酸酶σ抗体 Download PDFInfo
- Publication number
- CN103703372B CN103703372B CN201280020580.XA CN201280020580A CN103703372B CN 103703372 B CN103703372 B CN 103703372B CN 201280020580 A CN201280020580 A CN 201280020580A CN 103703372 B CN103703372 B CN 103703372B
- Authority
- CN
- China
- Prior art keywords
- antibody
- seq
- ptprs
- cells
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011-101752 | 2011-04-28 | ||
| JP2011101752 | 2011-04-28 | ||
| PCT/JP2012/061795 WO2012148003A1 (en) | 2011-04-28 | 2012-04-27 | ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103703372A CN103703372A (zh) | 2014-04-02 |
| CN103703372B true CN103703372B (zh) | 2018-01-26 |
Family
ID=46147004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280020580.XA Active CN103703372B (zh) | 2011-04-28 | 2012-04-27 | 抗‑人受体类型蛋白酪氨酸磷酸酶σ抗体 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9803026B2 (https=) |
| EP (2) | EP3232202B1 (https=) |
| JP (2) | JP6001557B2 (https=) |
| KR (1) | KR101873614B1 (https=) |
| CN (1) | CN103703372B (https=) |
| AU (2) | AU2012248158C1 (https=) |
| CA (1) | CA2834243C (https=) |
| ES (2) | ES2638088T3 (https=) |
| HU (2) | HUE054211T2 (https=) |
| IL (1) | IL229127A (https=) |
| MX (1) | MX352599B (https=) |
| PL (2) | PL3232202T3 (https=) |
| PT (2) | PT2702412T (https=) |
| RU (2) | RU2715642C2 (https=) |
| SG (3) | SG10202108240VA (https=) |
| WO (1) | WO2012148003A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2173379B2 (en) | 2007-07-02 | 2023-07-05 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
| PT2702412T (pt) * | 2011-04-28 | 2017-11-02 | Sbi Biotech Co Ltd | Anticorpo anti-proteína tirosina fosfatase humana do tipo recetor |
| JP6185463B2 (ja) | 2011-07-15 | 2017-08-23 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｒｓｐｏ結合剤およびその使用法 |
| US9181333B2 (en) * | 2012-07-13 | 2015-11-10 | Oncomed Pharmaceuticals, Inc. | RSPO3 binding agents and uses thereof |
| ES2817897T3 (es) * | 2012-07-23 | 2021-04-08 | La Jolla Inst Allergy & Immunology | PTPRS y proteoglicanos en enfermedad autoinmune |
| US11160873B2 (en) * | 2014-02-04 | 2021-11-02 | Monash University | Anti-metalloprotease antibody for diagnosis and treatment of cancers |
| WO2015117199A1 (en) * | 2014-02-04 | 2015-08-13 | Monash University | Anti-metalloprotease antibody for diagnosis and treatment of cancers |
| CA2961374A1 (en) | 2014-09-16 | 2016-03-24 | Oncomed Pharmaceuticals, Inc. | Treatment of fibrotic diseases |
| EP3633371A1 (en) * | 2014-12-18 | 2020-04-08 | F. Hoffmann-La Roche AG | Assay and method for determining cdc eliciting antibodies |
| SG11201908744PA (en) * | 2017-03-23 | 2019-10-30 | Univ Pennsylvania | Anti-c5a antibodies and uses thereof |
| US20200132673A1 (en) * | 2017-03-24 | 2020-04-30 | The Regents Of The University Of California | Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom |
| US11242398B2 (en) | 2017-08-01 | 2022-02-08 | Remd Biotherapeutics, Inc. | Anti-OX40 antibodies and methods of activating OX40 |
| US12054543B2 (en) | 2018-07-25 | 2024-08-06 | Accurus Biosciences, Inc. | CLDN 18.2-specific monoclonal antibodies and methods of use thereof |
| GB201910899D0 (en) * | 2019-07-31 | 2019-09-11 | Scancell Ltd | Binding members |
| IL291897A (en) | 2019-10-04 | 2022-06-01 | Albert Einstein College Medicine | Kir3dl3 inhibitory receptor of the immune system and its uses |
| WO2023010132A1 (en) | 2021-07-30 | 2023-02-02 | The Regents Of The University Of California | Ptprs in autoimmunity |
| CN114426582B (zh) * | 2022-01-07 | 2022-11-25 | 陕西脉元生物科技有限公司 | 一种神经特异性烯醇化酶单克隆抗体及其制备方法和应用 |
| CN116041526B (zh) * | 2022-11-14 | 2023-09-29 | 华中农业大学 | 一种鼠抗草鱼IgT单克隆抗体及其制备方法和应用 |
| WO2024124164A2 (en) * | 2022-12-09 | 2024-06-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of immunostimulatory cytokines to chimeric antigen receptor immune cells |
| JP2026507222A (ja) * | 2023-03-03 | 2026-02-27 | ケース ウエスタン リザーブ ユニバーシティ | 細胞接着分子を標的とする免疫療法 |
| CN118994384B (zh) * | 2024-08-09 | 2025-09-26 | 陕西脉元生物科技有限公司 | 抗Ri的人源化单克隆抗体及其应用和基于其的检测方法 |
| CN119874900B (zh) * | 2025-03-06 | 2025-10-17 | 吉林大学 | 一种单克隆抗体及其在制备治疗肿瘤药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0721352A4 (en) * | 1993-10-01 | 1998-07-01 | Univ New York | NEW PHOSPHOTYROSINE PHOSPHATASE - -g (s) WITH RECEPTOR FUNCTION |
| JP4498136B2 (ja) | 2002-08-01 | 2010-07-07 | Ｓｂｉバイオテック株式会社 | マウスインターフェロン産生細胞の検出方法 |
| RU2312109C2 (ru) * | 2003-03-14 | 2007-12-10 | Тайсо Фармасьютикал Ко., Лтд. | Моноклональное антитело и продуцирующая его гибридома |
| WO2005102456A1 (en) | 2004-03-27 | 2005-11-03 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Composition and method for cancer treatment |
| US20080008719A1 (en) | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
| WO2007041317A2 (en) | 2005-09-29 | 2007-04-12 | Viral Logic Systems Technology Corp. | Immunomodulatory compositions and uses therefor |
| WO2009003274A1 (en) | 2007-06-29 | 2009-01-08 | The Hospital For Sick Children | Susceptibility gene for inflammatory bowel disease |
| PT3130923T (pt) * | 2008-11-14 | 2020-06-17 | Brigham & Womens Hospital Inc | Métodos terapêuticos relacionados com células estaminais |
| US20120231014A1 (en) * | 2009-08-18 | 2012-09-13 | Case Western Reserve University | Neural Regeneration |
| EP2531859A4 (en) * | 2010-02-02 | 2013-07-31 | Jolla Inst Allergy Immunolog | Compositions and methods of modulating receptor protein tyrosine phosphatases |
| PT2702412T (pt) * | 2011-04-28 | 2017-11-02 | Sbi Biotech Co Ltd | Anticorpo anti-proteína tirosina fosfatase humana do tipo recetor |
-
2012
- 2012-04-27 PT PT127225571T patent/PT2702412T/pt unknown
- 2012-04-27 ES ES12722557.1T patent/ES2638088T3/es active Active
- 2012-04-27 JP JP2013549652A patent/JP6001557B2/ja active Active
- 2012-04-27 KR KR1020137028325A patent/KR101873614B1/ko active Active
- 2012-04-27 RU RU2017118262A patent/RU2715642C2/ru active
- 2012-04-27 AU AU2012248158A patent/AU2012248158C1/en active Active
- 2012-04-27 RU RU2013152816/10A patent/RU2013152816A/ru not_active Application Discontinuation
- 2012-04-27 PL PL17174348T patent/PL3232202T3/pl unknown
- 2012-04-27 SG SG10202108240VA patent/SG10202108240VA/en unknown
- 2012-04-27 ES ES17174348T patent/ES2788183T3/es active Active
- 2012-04-27 EP EP17174348.7A patent/EP3232202B1/en active Active
- 2012-04-27 PL PL12722557T patent/PL2702412T3/pl unknown
- 2012-04-27 SG SG10201503257WA patent/SG10201503257WA/en unknown
- 2012-04-27 HU HUE17174348A patent/HUE054211T2/hu unknown
- 2012-04-27 CN CN201280020580.XA patent/CN103703372B/zh active Active
- 2012-04-27 MX MX2013012393A patent/MX352599B/es active IP Right Grant
- 2012-04-27 HU HUE12722557A patent/HUE034752T2/en unknown
- 2012-04-27 US US14/113,904 patent/US9803026B2/en active Active
- 2012-04-27 CA CA2834243A patent/CA2834243C/en active Active
- 2012-04-27 PT PT171743487T patent/PT3232202T/pt unknown
- 2012-04-27 SG SG2013079066A patent/SG194614A1/en unknown
- 2012-04-27 WO PCT/JP2012/061795 patent/WO2012148003A1/en not_active Ceased
- 2012-04-27 EP EP12722557.1A patent/EP2702412B1/en active Active
-
2013
- 2013-10-28 IL IL229127A patent/IL229127A/en active IP Right Grant
-
2016
- 2016-09-01 JP JP2016170634A patent/JP6412072B2/ja active Active
- 2016-11-23 AU AU2016262677A patent/AU2016262677B2/en active Active
-
2017
- 2017-10-06 US US15/726,669 patent/US10730955B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103703372B (zh) | 抗‑人受体类型蛋白酪氨酸磷酸酶σ抗体 | |
| CN101379089B (zh) | 抗ilt7抗体 | |
| JP7244102B2 (ja) | 抗ホスホリパーゼｄ４抗体 | |
| BR112013027631B1 (pt) | Método para a produção de anticorpo monoclonal ou fragmento que inclui uma região de ligação ao antígeno do mesmo, anticorpo monoclonal ou um fragmento que inclui uma região de ligação ao antígeno do mesmo, hibridoma, método para a detecção de uma célula dendrítica plasmocitóide, uso de um anticorpo monoclonal ou um fragmento que inclui uma região de ligação ao antígeno do mesmo, e método ex vivo para suprimir a atividade de uma célula dendrítica plasmocitóide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |